PLUS vs SRPT · P/E 17, rev $2.07B vs rev $1.90B
ePlus inc (PLUS) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
PLUS currently screens at market cap $2.10B and trailing P/E 17.1. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the PLUS and SRPT stock pages for the full models.
Not investment advice.